Akums Drugs & Pharma reported a consolidated net profit of ₹1,009.78 million for the quarter ended June 30, 2026, marking a 56% year-on-year increase from ₹646.85 million in Q1FY26. Revenue from operations grew 14% to ₹11,666.29 million, supported by robust demand in its core CDMO business. The company’s Board of Directors approved these unaudited standalone and consolidated financial results on August 08, 2026, following a limited review by statutory auditors Walker Chandiok & Co LLP.

The results were filed pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Walker Chandiok & Co LLP issued an unmodified review report on both standalone and consolidated statements prepared under Ind AS 34. The auditor noted that the conclusion on consolidated results relies partly on other auditors’ reports for seven subsidiaries and unreviewed information for three others, which management deemed immaterial.

Financial Performance

Consolidated revenue from operations stood at ₹11,666.29 million, compared to ₹10,240.32 million in Q1FY26. Total income reached ₹11,970.09 million, including other income of ₹303.80 million. Profit before tax was ₹1,392.37 million, up from ₹956.46 million a year earlier. Tax expense totaled ₹382.59 million. Standalone net profit was ₹448.39 million, nearly flat at ₹448.67 million in Q1FY26, while standalone revenue rose 18% to ₹3,922.75 million.

Segment Highlights

The CDMO segment contributed ₹9,642.12 million in external revenue, up 18% year-on-year, with segment results before depreciation reaching ₹1,634.49 million. Domestic branded formulations revenue grew 7% to ₹1,152.79 million. The API segment saw a decline in external revenue to ₹316.46 million from ₹450.33 million, posting a segment loss of ₹81.46 million. Trade generics revenue fell to ₹209.44 million.

Key Developments

The company fully utilized its net IPO proceeds of ₹6,421.80 million towards stipulated objects, including debt repayment and working capital, leaving no unutilised funds as of June 30, 2026. Subsequent to the quarter end, subsidiary Pure and Cure Healthcare Private Limited approved the acquisition of Oriflame India Private Limited’s manufacturing business for ₹560.00 million, expanding capacity in color cosmetics and skincare.

Regulatory Matters

The Income Tax Department raised a consolidated tax demand of ₹1,560.18 million following search and seizure operations conducted in January 2025 for the block period April 2018 to March 2025. Akums has filed an appeal under Section 246A of the Income-Tax Act before the Commissioner of Income-tax (Appeals) and deposited ₹47.01 million as advance under protest post-quarter end. Management maintains that no material adjustments are required in the financial results based on legal opinions obtained.

What the Numbers Show

The divergence between standalone and consolidated profitability highlights the group structure's impact on earnings. While standalone profits remained flat, consolidated net profit surged 56%, indicating that subsidiaries—particularly those outside the direct manufacturing scope or involving higher-margin services—contributed disproportionately to growth. Additionally, finance costs included ₹200.54 million from unwinding significant financing components in customer advances, a non-cash item that inflated expenses but reflects long-term contract economics rather than operational debt burden.

Akums Drugs & Pharmaceuticals will host its quarterly earnings conference call on August 10, 2026, to discuss its un-audited financial results for the first quarter of fiscal year 2027 (Q1FY27). The event provides investors and analysts with an opportunity to review the company’s performance for the period ending June 30, 2026, directly with senior management. This disclosure ensures transparency regarding the company’s operational and financial standing in the initial quarter of the new fiscal year.

The conference call is scheduled to begin at 12:00 PM IST and will be conducted virtually. Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company notified the National Stock Exchange of India Ltd and BSE Limited of the schedule. The management has clarified that no unpublished price-sensitive information (UPSI) will be shared during the meet. The schedule remains subject to change due to exigencies on the part of investors or the company.

Management Participation

The session will feature key executives from Akums Drugs and Pharmaceuticals Limited. The management team participating in the discussion includes:

• Sanjeev Jain, Managing Director
• Sandeep Jain, Managing Director
• Sumeet Sood, Chief Financial Officer
• Sahil Maheshwari, Head Strategy

The teleconference will be moderated by Umesh Laddha from Institutional Equities at Ambit Capital.

Dial-in Details

Investors and analysts can join the virtual meeting using the access numbers provided below. Participants are advised to dial in a few minutes prior to the scheduled start time to avoid delays. Registration via Diamond Pass is available to bypass wait times.

The disclosure was signed by Dharamvir Malik, Company Secretary & Compliance Officer, on August 05, 2026. A copy of this intimation has been updated on the company’s website at www.akums.in for public record.